Portola Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference
12 Juin 2014 - 10:00PM
Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William
Lis, chief executive officer, will present at the 2014 Wells Fargo
Securities Healthcare Conference on Wednesday, June 18, at 8:20
a.m. Eastern Time in Boston.
The presentation will be webcast live and available for replay
from Portola's website at www.portola.com in the Investor Relations
section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that have the potential to represent
significant advances in the fields of thrombosis and other
hematologic diseases. The Company is advancing its three
wholly-owned programs using novel biomarker and genetic approaches
that may increase the likelihood of clinical, regulatory and
commercial success of its first-in-class therapies. Portola's
partnered program is focused on developing selective Syk inhibitors
for inflammatory conditions.
Betrixaban
Portola's wholly-owned, oral, once-daily Factor Xa inhibitor
betrixaban is being evaluated in the only biomarker-based Phase 3
study for hospital-to-home prophylaxis of venous thromboembolism
(VTE) in acute medically ill patients. Betrixaban's distinct
properties may have the potential to allow the agent to demonstrate
efficacy without the significant increase in the rate of major
bleeding that was seen in this patient population with other Factor
Xa inhibitors. If approved, betrixaban could be the first
anticoagulant for both hospital and post-discharge VTE prophylaxis
and the standard of care in this large market of more than 20
million patients worldwide.
Andexanet Alfa
Portola's second product candidate in the area of thrombosis,
andexanet alfa, has the potential to be a first-in-class antidote
to reverse the effects of Factor Xa inhibitors in patients who
suffer a major bleeding episode or who require emergency surgery.
Andexanet alfa has been designated as a breakthrough therapy by the
U.S. Food and Drug Administration. Portola has entered into
clinical collaboration agreements with all of the manufacturers of
direct Factor Xa inhibitors – Bristol-Myers Squibb and Pfizer
(Eliquis® [apixaban]), Bayer HealthCare and Janssen Pharmaceuticals
(XARELTO® [rivaroxaban]), and Daiichi Sankyo (edoxaban) – while
retaining all commercial rights to andexanet alfa.
Cerdulatinib* (PRT2070)
Portola's product candidate in the area of hematologic cancer,
cerdulatinib, is an orally available molecule that uniquely
inhibits two validated tumor proliferation pathways – spleen
tyrosine kinase (Syk) and janus kinase (JAK). It is currently being
evaluated in a Phase 1/2 proof-of-concept study in patients with
leukemias or lymphomas with a focus on genetically-defined
subtypes, as well as in patients who have failed therapy due to
relapse or acquired mutations.
For more information, visit www.portola.com and follow the
Company on Twitter @Portola_Pharma.
*Cerdulatinib is a proposed International Nonproprietary Name
(pINN).
CONTACT: Investor Contact:
Alexandra Santos
Portola Pharmaceuticals
ir@portola.com
650.246.7239
Media Contact:
Joey Fleury
BrewLife
jfleury@brewlife.com
415.946.1090
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024